Showing 1251-1260 of 1690 results for "".
Spinal Muscular Atrophy is Now a Treatable Genetic Condition
https://practicalneurology.com/diseases-diagnoses/neuromuscular/spinal-muscular-atrophy-is-now-a-treatable-genetic-condition/32025/Multiple therapy options are available for the treatment of people with spinal muscular atrophy, a genetic disorder presenting with a wide range of symptoms and severity.Catamenial Epilepsy
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/catamenial-epilepsy/31944/Understanding the underlying hormone pathophysiology and types of catamenial epilepsy is necessary for determining treatment options.Rehabilitation for People with Movement Disorders
https://practicalneurology.com/diseases-diagnoses/movement-disorders/rehabilitation-for-people-with-movement-disorders/32043/There are 2 main objectives to neurologic rehabilitation for people with movement disorders: 1) to maintain body structure and 2) to maximize functional skills.Improving Outcomes Earlier in Generalized Myasthenia Gravis: Roadmap for Incorporating Targeted Therapies Into Clinical Practice
https://reachmd.com/programs/cme/improving-outcomes-earlier-in-generalized-myasthenia-gravis-roadmap-for-incorporating-targeted-therapies-into-clinical-practice/29145/While traditional gMG treatments bring many debilitating side effects, a more targeted approach focusing on the FcRn complex has shown great promise.Digital Biomarkers in Neuromuscular Disorders: Recent Advances
https://practicalneurology.com/diseases-diagnoses/neuromuscular/digital-biomarkers-in-neuromuscular-disorders-recent-advances/35556/Digital health technologies have strong potential to aid in the study and management of neuromuscular conditions.Patient-Centric Innovations in MS Care: High-Efficacy DMTs, Cognition, and Special Patient Populations
https://practicalneurology.com/programs/cme/patient-centric-innovations-in-ms-care-high-efficacy-dmts-cognition-and-special-patient-populations/29171/Tune in to learn more about the use of high-efficacy DMTs in multiple sclerosis.Dementia Insights: Antiamyloid Antibody Therapy in Alzheimer Disease
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/dementia-insights-antiamyloid-antibody-therapy-in-alzheimer-disease/31928/The saga continues for development of antiamyloid monoclonal antibodies, aducanumab, lecanemab, donanemab, and gantenerumab for Alzheimer disease.Myasthenia Gravis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/myasthenia-gravis/31814/More treatments for myasthenia gravis are on the way.Emerging Therapies to Slow the Progression of Huntington Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/emerging-therapies-to-slow-the-progression-of-huntington-disease/31936/Although clinical trial results have been disappointing, they have moved development of potential disease-modifying treatments forward.Clinical Trials for Huntington Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/clinical-trials-for-huntington-disease/31681/The promise for potential disease-modifying research is strong, although continued discovery uncovers new questions and challenges to overcome.